Alzheimer's Disease

Found 820 articles

• AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

  2/28/2023

  AB Science SA announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease in the renowned international peer-reviewed journal Alzheimer's Research & Therapy.

• 

  Billy Dunn Steps Down from Post as FDA Neuroscience Head

  2/27/2023

  Billy Dunn, director of the FDA's Office of Neuroscience, is stepping down from his post to “explore other opportunities,” according to an internal FDA e-mail.

• Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

  2/22/2023

  Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease.

• Advocating for Alzheimer's Patients: Dr. Christopher Hancock Wins Leadership Award for Outstanding Contributions

  2/22/2023

  HALO Precision Diagnostics™ announced Christopher Hancock, MD, HALO's neuroscience innovation officer, will receive the Edie Keller Leadership Award for his outstanding contributions to Alzheimer's disease patient advocacy and clinical education from Alzheimers Coachella Valley at its annual Endless Possibilities event.

• Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE

  2/21/2023

  Cognito Therapeutics , a clinical-stage neurotechnology company, announced today the first patient enrollment in its US pivotal study (HOPE), designed to demonstrate the safety and efficacy of its proprietary non-invasive stimulation device CogTx-001 in patients with Alzheimer’s Disease.

• Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia

  2/21/2023

  Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia.

• 

  Eisai Anticipates Full Approval of Leqembi as Early as July

  2/17/2023

  If Leqembi is granted priority review from the agency, full approval could come as soon as July, Ivan Cheung, chairman and CEO, Eisai Inc., told CNBC Thursday.

• C2N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight

  2/16/2023

  C2N Diagnostics, LLC, a leader in advanced brain health diagnostics, announced it has received a $15 million program-related investment from GHR Foundation.

• 

  Biogen Expects Modest Leqembi Revenue as Aduhelm Takes Another Hit

  2/15/2023

  Biogen's 2022 fourth-quarter and full-year report comes the day after an additional warning on the company's first Alzheimer's drug came to light.

• Cure Alzheimer's Fund Appoints Drs. John S. Lazo and Patrick C. May to Research Strategy Council

  2/14/2023

  Cure Alzheimer's Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer's disease, is pleased to announce the appointment of Drs. John S. Lazo and Patrick C. May to its Research Strategy Council.

• Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

  2/8/2023

  Hoth Therapeutics, Inc.  today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.

• 

  Novel Biomarkers could Guide New Alzheimer’s Therapies

  2/6/2023

  The discovery of novel Alzheimer's biomarkers is enabling better trial selection, earlier pipeline decision making and new targets for therapeutics.

• Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010

  2/2/2023

  Oligomerix, Inc. today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010.

• Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

  2/1/2023

  Annovis Bio, Inc. announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues."

• ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

  1/31/2023

  ChromaDex Corp. announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu.

• Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

  1/31/2023

  Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2022 (Q2 FY23).

• 

  AC Immune Expands Vaccine Candidate to Down Syndrome

  1/26/2023

  Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.

• AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

  1/26/2023

  AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD).

• Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

  1/26/2023

  Coya Therapeutics, Inc. announced the recent publication of an article entitled “Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s Disease” in the peer reviewed journal Acta Neuropathologica Communications.

• Alzamend Neuro to Present at Sequire Biotechnology Conference

  1/26/2023

  Alzamend Neuro, Inc. today announced that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2, 2023.